CRL Charles River Laboratories
FY2025 10-K
Charles River Laboratories (CRL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 18, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Preclinical and clinical laboratory services for drug discovery and development
- • No new products, services, or business segments introduced or emphasized in this fiscal year
Management Discussion & Analysis
- • Revenue DSA declined in fiscal 2025 due to lower study volumes; RMS revenue increased driven by large research models and pricing; Manufacturing Microbial Solutions grew robustly
- • Goodwill impairment of $165M in Biologics Solutions for 2025 due to reduced performance; impairment $215M in 2024 in same unit
Risk Factors
- • Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair
- • Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution
Financial SummaryXBRL
Revenue
$4.0B
Net Income
-$144M
Operating Margin
0.6%
Net Margin
-3.6%
ROE
-4.6%
Total Assets
$7.1B
EPS (Diluted)
$-2.91
Operating Cash Flow
$738M
Source: XBRL data from Charles River Laboratories FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Charles River Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.